

Combination therapies for Parkinson's – Funding call 2025

To date, experimental treatments aimed to modify the progression of Parkinson's have focussed on monotherapies. However, Parkinson's is a complex condition, with many different biological pathways at play. Cure Parkinson's is interested in exploring combination therapies and the potential they have in disease modification.

Cure Parkinson's is delighted to announce a new, £2 million funding opportunity for researchers investigating combination therapies to treat Parkinson's.

Cure Parkinson's welcome applications from around the globe to test rationally designed combinations of two or more drugs with disease-modifying potential in Parkinson's. This call is open for both preclinical **and** clinical applications.

For preclinical projects, applicants can request up to £300,000. Cure Parkinson's and the independent evaluation panel will prioritise projects that are likely to lead to clinical trials in people with Parkinson's within five years.

For clinical studies, applicants can request in the region of £1million to fund clinical trials or sub-studies of trials evaluating drug combinations in people with Parkinson's.

Our full [Research Strategy](#) provides more information on the types of research we fund, our funding priorities and how we provide funding.

How to apply

Please complete the expression of interest form, drug CV (one for each agent) and commercial entity form (if applicable) in order to be considered for a full application.

To register your interest and be considered for full application, please complete the above-mentioned forms and email to research@cureparkinsons.org.uk by 11:59pm (GMT) on Monday 24 November 2025. Please note, applicants will be required to provide a justification for the combination of drugs proposed.

Cure Parkinson's will be hosting two, online question and answer (Q&A) sessions in the run up to the expression of interest deadline. The purpose of these seminars will be to give an overall picture of the combination therapy field, as well as provide an update of a recent workshop run by Cure Parkinson's exploring combination therapies. There will also be an opportunity to ask any questions you may have about this funding call.

Attendance to the Q&A sessions is not mandatory in order to submit an expression of interest. If an applicant is unable to attend either Q&A session but would still like to discuss their proposal, please get in touch with the Cure Parkinson's Research Team at research@cureparkinsons.org.uk.

Q&A sessions will be held at **10am (BST) Thursday 16 October 2025** and **4pm (GMT) Monday 3 November 2025**.

Call opens: Wednesday 1 October 2025

Q&A session 1: Thursday 16 October 2025, 10am (BST)

Q&A session 2: Monday 3 November 2025, 4pm (GMT)

Expression of interest deadline: Monday 24 November 2025, 11.59pm (GMT)

Invitation to full application: By Friday 5 December 2025

Full application deadline: Monday 26 January 2026, 11.59pm (GMT)

Anticipated result: May 2026

To be considered for funding, please complete the expression of interest form, drug CV (one for each agent) and commercial entity form (if applicable) and email to research@cureparkinsons.org.uk by **11.59pm (GMT) Monday 24 November 2025**.

Expressions of interest will be reviewed internally by the Cure Parkinson's research team and the independent panel Chair. Those most closely aligned with the goal of the funding call will be invited to submit a full application. The documents necessary for full application will be provided upon invitation by **Friday 5 December 2025**.

Only full applications that have been invited for full submission will be sent for external peer review and further considered for funding by an independent panel.

For more information about this funding call, please refer to the applicant guidance on our [website](#) or contact the Cure Parkinson's research team at research@cureparkinsons.org.uk.